SARLOGIA Trademark

Trademark Overview


On Thursday, November 15, 2018, a trademark application was filed for SARLOGIA with the United States Patent and Trademark Office. The USPTO has given the SARLOGIA trademark a serial number of 88195405. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 10, 2022. This trademark is owned by Allergan Sales, LLC. The SARLOGIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for usein the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and forfacial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetictreatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations forthe treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotion...
sarlogia

General Information


Serial Number88195405
Word MarkSARLOGIA
Filing DateThursday, November 15, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 10, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for usein the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and forfacial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetictreatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations forthe treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptivesponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations forthe treatment and prevention of urinaryincontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatmentof circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritablebowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations forthe prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases anddisorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervoussystem diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention andtreatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurologicaldisorders, neurodegenerative disorders,and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 3, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Monday, January 10, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 10, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, May 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 29, 2021EXTENSION 4 GRANTED
Thursday, April 29, 2021EXTENSION 4 FILED
Thursday, April 29, 2021TEAS EXTENSION RECEIVED
Friday, December 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 2, 2020EXTENSION 3 GRANTED
Wednesday, December 2, 2020EXTENSION 3 FILED
Wednesday, December 2, 2020TEAS EXTENSION RECEIVED
Friday, May 1, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 29, 2020EXTENSION 2 GRANTED
Wednesday, April 29, 2020EXTENSION 2 FILED
Wednesday, April 29, 2020TEAS EXTENSION RECEIVED
Saturday, November 23, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 21, 2019EXTENSION 1 GRANTED
Thursday, November 21, 2019EXTENSION 1 FILED
Thursday, November 21, 2019TEAS EXTENSION RECEIVED
Tuesday, June 4, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 9, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 9, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 26, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 20, 2019ASSIGNED TO EXAMINER
Monday, December 3, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, November 19, 2018NEW APPLICATION ENTERED IN TRAM